InvestorsHub Logo
Followers 4
Posts 21
Boards Moderated 0
Alias Born 01/25/2021

Re: None

Wednesday, 05/04/2022 7:43:00 AM

Wednesday, May 04, 2022 7:43:00 AM

Post# of 425
Annovis Bio's new entry on ClinicalTrials.gov for Phase 3 Parkinson's Disease: https://clinicaltrials.gov/ct2/show/NCT05357989?term=annovis&draw=2&rank=2

Study start: June 2022
Primary completion: January 2023
Study completion: March 2023
(all estimated dates)

Company is at less than $82M market cap with around $20M in cash and one proven phase 3 asset in PD with promising interim results... This is insanely undervalued!!!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ANVS News